Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)

BACKGROUND: Despite most metastatic castration-resistant prostate cancer (mCRPC) patients benefit from abiraterone acetate plus prednisone 5 mg bid (AA + P), resistance eventually occurs. Long-term use of prednisone has been suggested as one of the mechanisms driving resistance, which may be reverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Romero-Laorden, Nuria, Lozano, Rebeca, Jayaram, Anuradha, López-Campos, Fernando, Saez, Maria I., Montesa, Alvaro, Gutierrez-Pecharoman, Ana, Villatoro, Rosa, Herrera, Bernardo, Correa, Raquel, Rosero, Adriana, Pacheco, María I., Garcés, Teresa, Cendón, Ylenia, Nombela, Ma Paz, Van de Poll, Floortje, Grau, Gala, Rivera, Leticia, López, Pedro P., Cruz, Juan-Jesús, Lorente, David, Attard, Gerhardt, Castro, Elena, Olmos, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219494/
https://www.ncbi.nlm.nih.gov/pubmed/30131546
http://dx.doi.org/10.1038/s41416-018-0123-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219494/
https://www.ncbi.nlm.nih.gov/pubmed/30131546
http://dx.doi.org/10.1038/s41416-018-0123-9

Ejemplares similares